Clinical Observation of Xianlinggubao Combined with Alendronate Sodium in the Treatment of Osteopo-rosis
10.6039/j.issn.1001-0408.2016.17.29
- VernacularTitle:仙灵骨葆联合阿仑膦酸钠治疗骨质疏松症的临床观察
- Author:
Xiaosheng HOU
;
Wenxiao JIANG
;
Jian ZHUANG
- Publication Type:Journal Article
- Keywords:
Osteoporosis;
Xianlinggubao capsule;
Alendronate sodium;
Clinical efficacy;
Safety
- From:
China Pharmacy
2016;27(17):2391-2393
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe clinical efficacy and safety of Xianlinggubao combined with alendronate sodium in the treatment of osteoporosis. METHODS:112 patients with osteoporosis were randomly divided into treatment group and control group with 56 cases in each group. Both group were given routine treatment as calcium carbonate,vitamin D and life style. Control group were given alendronate sodium 10 mg orally,qd;treatment group was additionally given Xianlinggubao capsule 1.5 g,bid, on the basis of control group. Both groups received 12 weeks of treatment. The levels of S-Ca,S-P,24 h urinary calcium(U-Ca), alkaline phosphatase(ALP),osteocalcin,IL-6,bone mineral density(BMD)of L2-4 lumbar spine and femoral neck were observed in 2 groups before and after treatment. Clinical efficacy and toxic reaction were compared. RESULTS:There was no statistical sig-nificance in the levels of S-P and S-Ca between 2 groups after treatment(P>0.05);the level of ALP、osteocalcin、BMD increased in treatment group after treatment,the level of U-Ca and IL-6 decreased compared to before treatment,and the treatment group was better than the control group,with statistical significance(P<0.05). Total effective rate of treatment group(92.86%)was sig-nificantly higher than that of control group (73.21%),with statistical significance (P<0.05). No obvious toxic side effects was found in 2 groups. CONCLUSIONS:Xianlinggubao combined with alendronate sodium shows significant therapeutic efficacy for patients with osteoporosis with good safety.
